Comparative analysis of p16 expression among African American and European American prostate cancer patients

Myra Wong, Yaeli Bierman, Curtis Pettaway, Rick A Kittles, Martha Mims, Jeffrey Jones, Michael Ittmann

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Expression of p16 is increased in a number of malignancies, including prostate cancer (PCa). Recent studies in a European cohort showed that expression of p16 is correlated with expression of the TMPRSS2/ERG (T/E) fusion protein. The T/E fusion is significantly less common in PCas in African American (AA) men. Thus, it would be predicted that p16 expression should be less common in PCas in AA men. We, therefore, sought to compare the expression of p16 in benign prostate and PCas from AA and European American (EA) men. Methods: Immunohistochemistry for p16 and ERG was performed on tissue microarrays constructed from radical prostatectomies performed on AA and EA veterans. Staining was scored and the scores compared with demographic, clinical and pathological parameters. Percent of West African ancestry in the AA cohort was assessed using ancestry informative markers. Results: Contrary to our predictions, p16 expression was similar in the cancers in the AA and EA cohorts. Consistent with prior reports, expression of p16 was quite low in benign prostate tissues from EA patients but surprisingly was significantly higher in benign tissues from AA patients. Expression of p16 was significantly associated with a family history of PCa in AA men. In addition, p16 was associated with ERG expression in AA PCa. Conclusions: While overall expression of p16 is similar in PCas from the two racial groups, the expression of p16 in benign tissues from a subset of AA men and the stronger correlation with ERG expression implies that there are different mechanisms for p16 overexpression in PCas from the two racial groups.

Original languageEnglish (US)
Pages (from-to)1274-1283
Number of pages10
JournalProstate
Volume79
Issue number11
DOIs
StatePublished - Aug 1 2019

Fingerprint

African Americans
Prostatic Neoplasms
Prostate
Veterans
Prostatectomy
Neoplasms
Immunohistochemistry
Demography
Staining and Labeling

Keywords

  • African American
  • p16
  • prostate cancer
  • TMPRSS2/ERG

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Comparative analysis of p16 expression among African American and European American prostate cancer patients. / Wong, Myra; Bierman, Yaeli; Pettaway, Curtis; Kittles, Rick A; Mims, Martha; Jones, Jeffrey; Ittmann, Michael.

In: Prostate, Vol. 79, No. 11, 01.08.2019, p. 1274-1283.

Research output: Contribution to journalArticle

Wong, M, Bierman, Y, Pettaway, C, Kittles, RA, Mims, M, Jones, J & Ittmann, M 2019, 'Comparative analysis of p16 expression among African American and European American prostate cancer patients', Prostate, vol. 79, no. 11, pp. 1274-1283. https://doi.org/10.1002/pros.23833
Wong, Myra ; Bierman, Yaeli ; Pettaway, Curtis ; Kittles, Rick A ; Mims, Martha ; Jones, Jeffrey ; Ittmann, Michael. / Comparative analysis of p16 expression among African American and European American prostate cancer patients. In: Prostate. 2019 ; Vol. 79, No. 11. pp. 1274-1283.
@article{ae3a7f22da8b471492ecd1b9492e79a9,
title = "Comparative analysis of p16 expression among African American and European American prostate cancer patients",
abstract = "Background: Expression of p16 is increased in a number of malignancies, including prostate cancer (PCa). Recent studies in a European cohort showed that expression of p16 is correlated with expression of the TMPRSS2/ERG (T/E) fusion protein. The T/E fusion is significantly less common in PCas in African American (AA) men. Thus, it would be predicted that p16 expression should be less common in PCas in AA men. We, therefore, sought to compare the expression of p16 in benign prostate and PCas from AA and European American (EA) men. Methods: Immunohistochemistry for p16 and ERG was performed on tissue microarrays constructed from radical prostatectomies performed on AA and EA veterans. Staining was scored and the scores compared with demographic, clinical and pathological parameters. Percent of West African ancestry in the AA cohort was assessed using ancestry informative markers. Results: Contrary to our predictions, p16 expression was similar in the cancers in the AA and EA cohorts. Consistent with prior reports, expression of p16 was quite low in benign prostate tissues from EA patients but surprisingly was significantly higher in benign tissues from AA patients. Expression of p16 was significantly associated with a family history of PCa in AA men. In addition, p16 was associated with ERG expression in AA PCa. Conclusions: While overall expression of p16 is similar in PCas from the two racial groups, the expression of p16 in benign tissues from a subset of AA men and the stronger correlation with ERG expression implies that there are different mechanisms for p16 overexpression in PCas from the two racial groups.",
keywords = "African American, p16, prostate cancer, TMPRSS2/ERG",
author = "Myra Wong and Yaeli Bierman and Curtis Pettaway and Kittles, {Rick A} and Martha Mims and Jeffrey Jones and Michael Ittmann",
year = "2019",
month = "8",
day = "1",
doi = "10.1002/pros.23833",
language = "English (US)",
volume = "79",
pages = "1274--1283",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Comparative analysis of p16 expression among African American and European American prostate cancer patients

AU - Wong, Myra

AU - Bierman, Yaeli

AU - Pettaway, Curtis

AU - Kittles, Rick A

AU - Mims, Martha

AU - Jones, Jeffrey

AU - Ittmann, Michael

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Expression of p16 is increased in a number of malignancies, including prostate cancer (PCa). Recent studies in a European cohort showed that expression of p16 is correlated with expression of the TMPRSS2/ERG (T/E) fusion protein. The T/E fusion is significantly less common in PCas in African American (AA) men. Thus, it would be predicted that p16 expression should be less common in PCas in AA men. We, therefore, sought to compare the expression of p16 in benign prostate and PCas from AA and European American (EA) men. Methods: Immunohistochemistry for p16 and ERG was performed on tissue microarrays constructed from radical prostatectomies performed on AA and EA veterans. Staining was scored and the scores compared with demographic, clinical and pathological parameters. Percent of West African ancestry in the AA cohort was assessed using ancestry informative markers. Results: Contrary to our predictions, p16 expression was similar in the cancers in the AA and EA cohorts. Consistent with prior reports, expression of p16 was quite low in benign prostate tissues from EA patients but surprisingly was significantly higher in benign tissues from AA patients. Expression of p16 was significantly associated with a family history of PCa in AA men. In addition, p16 was associated with ERG expression in AA PCa. Conclusions: While overall expression of p16 is similar in PCas from the two racial groups, the expression of p16 in benign tissues from a subset of AA men and the stronger correlation with ERG expression implies that there are different mechanisms for p16 overexpression in PCas from the two racial groups.

AB - Background: Expression of p16 is increased in a number of malignancies, including prostate cancer (PCa). Recent studies in a European cohort showed that expression of p16 is correlated with expression of the TMPRSS2/ERG (T/E) fusion protein. The T/E fusion is significantly less common in PCas in African American (AA) men. Thus, it would be predicted that p16 expression should be less common in PCas in AA men. We, therefore, sought to compare the expression of p16 in benign prostate and PCas from AA and European American (EA) men. Methods: Immunohistochemistry for p16 and ERG was performed on tissue microarrays constructed from radical prostatectomies performed on AA and EA veterans. Staining was scored and the scores compared with demographic, clinical and pathological parameters. Percent of West African ancestry in the AA cohort was assessed using ancestry informative markers. Results: Contrary to our predictions, p16 expression was similar in the cancers in the AA and EA cohorts. Consistent with prior reports, expression of p16 was quite low in benign prostate tissues from EA patients but surprisingly was significantly higher in benign tissues from AA patients. Expression of p16 was significantly associated with a family history of PCa in AA men. In addition, p16 was associated with ERG expression in AA PCa. Conclusions: While overall expression of p16 is similar in PCas from the two racial groups, the expression of p16 in benign tissues from a subset of AA men and the stronger correlation with ERG expression implies that there are different mechanisms for p16 overexpression in PCas from the two racial groups.

KW - African American

KW - p16

KW - prostate cancer

KW - TMPRSS2/ERG

UR - http://www.scopus.com/inward/record.url?scp=85068047275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068047275&partnerID=8YFLogxK

U2 - 10.1002/pros.23833

DO - 10.1002/pros.23833

M3 - Article

C2 - 31111520

AN - SCOPUS:85068047275

VL - 79

SP - 1274

EP - 1283

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 11

ER -